RecruitingNot ApplicableNCT06483737

Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)

Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE): an Invesitgator-initiated, Open-label, Multicenter, Randomized Controlled Trial

Sponsor

General Hospital of Shenyang Military Region

Enrollment

174 participants

Start Date

Jun 24, 2025

Study Type

INTERVENTIONAL

Conditions

Overt Hepatic Encephalopathy

Summary

Hepatic encephalopathy (HE), a severe complication of decompensated cirrhosis, is characterized as neurocognitive dysfunction. Emerging evidence suggests the potential role of human albumin infusion for the treatment of HE, but its optimal dosage remains undefined. Therefore, the investigators planned a randomized controlled trial (RCT) to compare the efficacy of human albumin infusion at different dosages in in patients with liver cirrhosis and overt HE.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Arginine, a drug called Branched-Chain Amino Acids, and others for people with overt hepatic encephalopathy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHuman albumin infusion at a modified dosage

Participants receive intravenous infusion of human albumin at different dosages according to the serum albumin level.

DRUGHuman albumin infusion at a routine dosage

Participants receive intravenous infusion of human albumin according to the current clinical practice.

DRUGLactulose